Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals ( (EYPT) ) has issued an update.
On October 14, 2025, EyePoint Pharmaceuticals announced the initiation of its pivotal Phase 3 program for DURAVYU, targeting diabetic macular edema (DME), with first patient dosing expected in Q1 2026. The program follows a non-inferiority approval pathway and includes two trials, COMO and CAPRI, each enrolling approximately 240 patients. New preclinical data highlights DURAVYU’s potential as a multi-mechanism treatment, inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, which are key contributors to DME and wet AMD. This advancement positions DURAVYU as a promising option for addressing the multifactorial nature of DME and reducing treatment burdens for patients.
The most recent analyst rating on (EYPT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
EyePoint Pharmaceuticals’ stock score is driven by strong technical momentum and positive clinical trial progress, offset by financial challenges and valuation concerns. The company’s robust cash position and strategic focus on innovative treatments provide a foundation for potential future growth, but current profitability issues and overbought technical indicators suggest caution.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a company focused on developing and commercializing innovative therapeutics for serious retinal diseases. Their primary product, DURAVYU, is a sustained-delivery treatment designed for retinal conditions such as diabetic macular edema (DME) and wet age-related macular degeneration (AMD).
Average Trading Volume: 840,421
Technical Sentiment Signal: Buy
Current Market Cap: $935.3M
See more data about EYPT stock on TipRanks’ Stock Analysis page.